Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

Tyson (TSN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.